-
Hot Stock List: Histogenics Corporation (NASDAQ:HSGX), FibroGen (NASDAQ:FGEN), Crossroads Systems (NASDAQ:CRDS), BGC Partners (NASDAQ:BGCP), Five Prime Therapeutics (NASDAQ:FPRX)
On Thursday shares of Histogenics Corporation (NASDAQ:HSGX) closed at $7.88. Histogenics Corporation (NASDAQ:HSGX), announced its financial and operational results for the first quarter ended March 31, 2015. For the first quarter of 2015, Histogenics reported a net loss of $(8.0) million, or $(0.60) per share, compared to a net loss of $(3.4) million, or $(5.90)…
-
Moving Stocks: FibroGen (NASDAQ:FGEN), Immunomedics Inc. (NASDAQ:IMMU), Southwestern Energy Co. (NYSE:SWN), Voya Financial (NYSE:VOYA), Healthcare Trust of America (NYSE:HTA)
On Thursday shares of FibroGen, Inc. (NASDAQ:FGEN) closed at $23.86. FibroGen, Inc. (NASDAQ:FGEN) announced that it has received a $15 million milestone payment from AstraZeneca AB (“AstraZeneca”), triggered by the completion of roxadustat non-clinical carcinogenicity studies. In two separate two-year carcinogenicity studies, in rats and in mice, there was no evidence of a roxadustat-related effect…
-
News Buzz: Aldeyra Therapeutics (NASDAQ:ALDX), FibroGen (NASDAQ:FGEN), Apple Inc. (NASDAQ:AAPL), UTi Worldwide Inc. (NASDAQ:UTIW), RPX Corporation (NASDAQ:RPXC)
On Monday shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) closed at $10.12. On March 19, it was reported that, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced that it has started patient enrolment in a phase II study on its investigational candidate NS2 for the treatment of Sjögren-Larsson syndrome. Apart from Sjögren-Larsson syndrome, the candidate is being developed for…
-
Top Morning News: FibroGen (NASDAQ:FGEN), Sysorex Global Holdings Corp. (NASDAQ:SYRX), The TJX Companies (NYSE:TJX), Nordstrom Inc. (NYSE:JWN), AT&T (NYSE:T)
FibroGen (NASDAQ:FGEN) was downgraded by research analysts at Goldman Sachs from a “buy” rating to a “neutral” rating in a report released on Friday, TheFlyOnTheWall.com reports. They currently have a $32.00 target price on the stock. Goldman Sachs’ price objective suggests a potential downside of 5.60% from the stock’s previous close. On Tuesday shares of…
-
Top Biotech Losers: Advaxis (NASDAQ:ADXS), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Otonomy (NASDAQ:OTIC), Enanta Pharmaceuticals (NASDAQ:ENTA), FibroGen (NASDAQ:FGEN)
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. On Thursday shares of Advaxis, Inc. (NASDAQ:ADXS)…
-
Biotech Stocks Touched New Highs: NPS Pharmaceuticals (NASDAQ:NPSP), Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Kite Pharma (NASDAQ:KITE), bluebird bio (NASDAQ:BLUE), FibroGen (NASDAQ:FGEN)
NPS Pharmaceuticals (NASDAQ:NPSP) Director Rachel R. Selisker sold 3,708 shares of the stock on the open market in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $34.59, for a total value of $128,259.72. Following the completion of the transaction, the director now directly owns 7,400 shares…
-
Biotech Bullish Movers: Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), FibroGen (NASDAQ:FGEN), Galmed Pharmaceuticals (NASDAQ:GLMD), Protalix BioTherapeutics (NYSEMKT:PLX), Vitae Pharmaceuticals (NASDAQ:VTAE)
According to the Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s press release, it will report top-line results from three clinical trials in subjects with varying degrees of organ impairment. The company will announce Phase 2 trial results in patients with acute-on-chronic liver failure (ACLF), a Phase 1 trial in patients with mild, moderate and severe hepatic impairment and…